Pacific Biosciences Announces Fourth Quarter 2015 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/26/2026
- Wall Street stocks end tad lower after hot inflation data ahead of Nvidia earnings
- Nvidia forecasts quarterly revenue above estimates, shares rise
- Oil settles down after choppy session as investors weigh Hormuz talks
- Meta to pay up to $16.68 billion in mass social media settlement
- Anthropic agrees to $45bn cloud computing deal with Nscale - report
- Nutanix (NTNX) Tops Q4 EPS by 11c, Beats in Revenue; Offers Q1 Revenue Guidance
- Boston Scientific discloses cybersecurity incident causing global disruption
- Crude Inventory Rose 0.1 Million Barrels Last Week - EIA
- Wall Street ends higher as tech rebounds before Nvidia results
- Six Flags to move headquarters from Charlotte to Arlington, Texas
Piper Jaffray Downgrades Pacific Biosciences of California (PACB) to Neutral
February 4, 2016 6:37 AM ESTPiper Jaffray downgraded Pacific Biosciences of California (NASDAQ: PACB) from Overweight to Neutral with a price target of $11.00 (from $9.00).
Analyst William Quirk commented, "PacBio reported 4Q15 revenue of $36.3M, ~in line with the Street's $36.6M forecast. EPS of $(0.02) was also in line. PacBio... More
Pacific Bio (PACB) Reports In-Line Q4 EPS
February 3, 2016 5:08 PM ESTPacific Bio (NASDAQ: PACB) reported Q4 EPS of ($0.02), in-line with the analyst estimate of ($0.02). Revenue for the quarter came in at $36.3 million versus the consensus estimate of $36.96 million.
For earnings history and earnings-related data on Pacific Bio (PACB) click here.
... More